POINT Biopharma, IONETIX in Ac-225 supply agreement

POINT Biopharma Global (NASDAQ:PNT) and IONETIX, a leading cyclotron technology and isotope manufacturing company, entered into a long-term supply agreement for actinium-225 (Ac-225) to support POINT’s validation, drug development, and clinical trials for Ac-225-based radiopharmaceuticals.

POINT plans to use Ac-225 in investigational studies of PNT2001, a next-generation prostate-specific membrane antigen directed radioligand for non-metastatic castrate-sensitive prostate cancer, and PNT2004, a fibroblast activation protein-alpha inhibitor candidate with potential pan-cancer applications.

“Our partnership with IONETIX further strengthens our robust radioisotope supply chain and continues to advance our next-generation radiopharmaceutical platform,” Dr. Joe McCann, CEO of POINT, said in a statement. 

“We are actively investing in technologies, such as our CanSEEK tumor microenvironment prodrug technology, to further extend the usage of potent alpha emitting medical isotopes like Ac-225, as we believe they have a key role to play in the future of radiopharmaceuticals,” he added.

Kevin Cameron, chairman of IONETIX, said alpha radionuclides like astatine-211 and actinium-225 hold significant promise for radiopharmaceuticals and … potentially life-altering therapies.

“Our proprietary cyclotron technology and growing distribution network, positions us to deliver alpha radionuclide therapeutics that would otherwise not be possible,” he added. 

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.